ストックスクリーナーアプリを入手
5.35
8.08%
0.40
アフターアワーズ：
5.38
0.03
+0.56%
Atyr Pharma Inc (ATYR) 最新ニュース
What institutional flow reveals about aTyr Pharma Inc.Long Setup & Weekly High Return Stock Opportunities - Newser
How to track smart money flows in aTyr Pharma Inc.Weekly Profit Summary & Risk Managed Investment Entry Signals - Newser
Is it too late to sell aTyr Pharma Inc.Risk Management & Real-Time Buy Signal Alerts - Newser
How to use a screener to detect aTyr Pharma Inc. breakoutsQuarterly Earnings Report & Technical Entry and Exit Alerts - Newser
Moving Average Crossover Confirms Uptrend in aTyr Pharma Inc.2025 Bull vs Bear & Stepwise Trade Execution Plans - beatles.ru
aTyr Pharma Inc.’s volatility index tracking explainedJuly 2025 Pullbacks & Weekly Chart Analysis and Guides - Newser
ATyr Pharma Rated as Overweight at Cantor Fitzgerald on Efzofitimod Expectations - Yahoo Finance
Live market analysis of aTyr Pharma Inc.Gold Moves & Free Safe Capital Growth Stock Tips - Newser
Is aTyr Pharma Inc. stock bottoming outBreakout Watch & Free Growth Oriented Trading Recommendations - Newser
Analyzing drawdowns of aTyr Pharma Inc. with statistical tools2025 Valuation Update & Real-Time Stock Movement Alerts - Newser
What makes aTyr Pharma Inc. stock price move sharplyNew Guidance & High Return Stock Watch Alerts - beatles.ru
Technical analysis overview for aTyr Pharma Inc. stockQuarterly Profit Review & AI Based Buy and Sell Signals - Newser
Developing predictive dashboards with aTyr Pharma Inc. dataEarnings Risk Summary & Real-Time Price Movement Reports - Newser
High Growth US Tech Stocks To Watch In August 2025 - Yahoo Finance
RSI Crosses Above 30 for aTyr Pharma Inc. — Reversal in SightTrade Analysis Summary & Daily Stock Trend Reports - beatles.ru
Regression analysis insights on aTyr Pharma Inc. performanceEarnings Risk Report & AI Driven Stock Reports - Newser
aTyr Pharma: Estimating Their Phase 3 Lung Disease Trial Outcome (NASDAQ:ATYR) - Seeking Alpha
Does aTyr Pharma Inc. qualify in momentum factor screeningMarket Activity Summary & Weekly High Return Stock Forecasts - Newser
Risk adjusted return profile for aTyr Pharma Inc. analyzed2025 Key Lessons & Breakout Confirmation Alerts - Newser
Heatmap analysis for aTyr Pharma Inc. and competitorsWeekly Trade Review & Verified Short-Term Plans - Newser
Is aTyr Pharma Inc. a play on infrastructure spendingDividend Hike & Daily Growth Stock Tips - newsimpact.co.kr
Applying Elliott Wave Theory to aTyr Pharma Inc.Weekly Gains Report & Risk Adjusted Buy/Sell Alerts - Newser
How to escape a deep drawdown in aTyr Pharma Inc.2025 Year in Review & Short-Term Trading Opportunity Alerts - Newser
Can machine learning forecast aTyr Pharma Inc. recoveryIndex Update & AI Forecasted Entry and Exit Points - Newser
Is aTyr Pharma Inc. exposed to currency risksTrend Reversal & AI Enhanced Trade Execution Alerts - thegnnews.com
XTX Topco Ltd Has $59,000 Stock Holdings in aTyr Pharma, Inc. (NASDAQ:ATYR) - Defense World
Trendlines Suggest aTyr Pharma Inc. May Bottom Out SoonTechnical Breakout Signal Plan Strategy - beatles.ru
Optimistic Outlook for aTyr Pharma Amidst Controversies: Analyst Highlights Potential in EFZO-FIT Study - TipRanks
Custom Dashboard Highlights aTyr Pharma Inc. Price MomentumEarnings Miss & Free Growth Oriented Trading Recommendations - sundaytimes.kr
aTyr Pharma Inc. Shows Support at Fibonacci LevelJuly 2025 EndofMonth & Fast Moving Market Watchlists - newsyoung.net
Published on: 2025-08-14 00:58:46 - Newser
Analysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG), Cullinan Management (CGEM) and aTyr Pharma (ATYR) - The Globe and Mail
Will aTyr Pharma Inc. Bounce From 52 Week LowPotential Breakout Stock List Published This Week - sundaytimes.kr
ATYR.O Plummets 7.8%: A Deep Dive into the Unusual Intraday Move - AInvest
aTyr Pharma Inc. Outperforms Peers on Volume MetricsSwing Setup With Technical Confirmation Explained - 선데이타임즈
Optimistic Buy Rating for aTyr Pharma Amid Promising Phase 3 Data and Innovative Sarcoidosis Treatment Approach - TipRanks
aTyr Pharma, Inc. (NASDAQ:ATYR) Given Consensus Rating of “Buy” by Brokerages - Defense World
aTyr Pharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Traders Consider Averaging Down in aTyr Pharma Inc.Entry Alert Based on Volume Spikes Detected - metal.it
Promising Developments and Strong Financial Position Drive Buy Rating for aTyr Pharma - TipRanks
1 Small-Cap Biotech Stock Poised for a Breakout - AOL.com
Connect Biopharma Holdings Limited shares rise 1.93% intraday after aTyr Pharma announced Phase 3 EFZO-FIT™ study completion. - AInvest
aTyr Pharma Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
3 Innovation Stocks With Parabolic Upside Potential - AOL.com
Atyr Pharma: Q2 Earnings Snapshot - Connecticut Post
aTyr Pharma Reports Q2 2025 Financial Results - TipRanks
aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update - GlobeNewswire
aTyr Pharma reports Q2 EPS (22c), consensus (18c) - TipRanks
ATYR Stock: A Comprehensive Analysis and Forecast - investchronicle.com
0.94%
1.72%
大文字化:
|
ボリューム (24 時間):